Predicting the outcome of ankylosing spondylitis therapy

Predicting the outcome of ankylosing spondylitis therapy

Objectives To create a model that provides a potential basis for candidate selection for anti-tumour necrosis factor (TNF) treatment by predicting future outcomes relative to the current disease profile of individual patients with ankylosing spondylitis (AS). Methods ASSERT and GO–RAISE trial data (...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Nathan Vastesaeger, Désirée van der Heijde, Robert D. Inman, Yanxin Wang, Atul Deodhar, Benjamin Hsu, Mahboob U. Rahman, Ben A. C. Dijkmans, Piet Geusens, Bert Vander Cruyssen, Eduardo Collantes‐Estévez, Joachim Sieper, Jürgen Braun
Format:	Artigo
Langue:	anglais
Publié:	2011
Accès en ligne:	https://doi.org/10.1136/ard.2010.147744 https://ard.bmj.com/content/annrheumdis/70/6/973.full.pdf
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Predicting the outcome of ankylosing spondylitis therapy
par: Vastesaeger, Nathan, et autres
Publié: (2011)

Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery
par: Bert Vander Cruyssen, et autres
Publié: (2009)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
par: van der Heijde, Désirée, et autres
Publié: (2019)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
par: Désirée van der Heijde, et autres
Publié: (2018)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
par: Braun, Jürgen, et autres
Publié: (2011)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
par: Jürgen Braun, et autres
Publié: (2011)

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
par: Wagner, Carrie, et autres
Publié: (2011)

Ankylosing spondylitis: an overview
par: Joachim Sieper, et autres
Publié: (2002)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
par: Deodhar, Atul, et autres
Publié: (2015)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
par: Atul Deodhar, et autres
Publié: (2014)

Anti-tumour necrosis factor α therapy for ankylosing spondylitis: international experience
par: Braun, J, et autres
Publié: (2002)

The Effect of Golimumab Therapy on Disease Activity and Health-related Quality of Life in Patients with Ankylosing Spondylitis: 2-year Results of the GO-RAISE Trial
par: Désirée van der Heijde, et autres
Publié: (2014)

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
par: Dominique Baeten, et autres
Publié: (2015)

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis
par: Jürgen Braun, et autres
Publié: (2005)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
par: Jürgen Braun, et autres
Publié: (2011)

Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
par: Jürgen Braun, et autres
Publié: (2023)

Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study
par: Inman, Robert D., et autres
Publié: (2016)

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
par: Xenofon Baraliakos, et autres
Publié: (2023)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
par: Braun, Jürgen, et autres
Publié: (2014)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
par: Jürgen Braun, et autres
Publié: (2013)

The epidemiology of ankylosing spondylitis and the commencement of anti‐TNF therapy in daily rheumatology practice
par: Cruyssen, Bert Vander, et autres
Publié: (2007)

The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice
par: Bert Vander Cruyssen, et autres
Publié: (2007)

Spinal Radiographic Changes in Ankylosing Spondylitis: Association with Clinical Characteristics and Functional Outcome
par: Annelies Boonen, et autres
Publié: (2009)

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
par: Braun, Jürgen, et autres
Publié: (2018)

The epidemiology of osteoporosis and fractures in ankylosing spondylitis
par: Sambrook, Philip N., et autres
Publié: (2012)

The epidemiology of osteoporosis and fractures in ankylosing spondylitis
par: Philip N. Sambrook, et autres
Publié: (2012)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
par: Braun, Jürgen, et autres
Publié: (2011)

ASAS/EULAR recommendations for the management of ankylosing spondylitis
par: Zochling, J, et autres
Publié: (2006)

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
par: Désirée van der Heijde, et autres
Publié: (2022)

Etanercept in the Longterm Treatment of Patients With Ankylosing Spondylitis
par: Ben A. C. Dijkmans, et autres
Publié: (2009)

Ankylosing spondylitis: an overview
par: Sieper, J, et autres
Publié: (2002)

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
par: Sudha Visvanathan, et autres
Publié: (2008)

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
par: Braun, J, et autres
Publié: (2011)

Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches.
par: Jürgen Braun, et autres
Publié: (2002)

Definition of disease duration in ankylosing spondylitis: reassessing the concept
par: Davis, J C, et autres
Publié: (2006)

Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis
par: Désirée van der Heijde, et autres
Publié: (2007)

Staging of patients with ankylosing spondylitis: a preliminary proposal
par: Braun, J, et autres
Publié: (2002)

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
par: Désirée van der Heijde, et autres
Publié: (2008)

Determinants of hyperkyphosis in patients with ankylosing spondylitis
par: Vosse, D, et autres
Publié: (2006)

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
par: Jürgen Braun, et autres
Publié: (2016)